Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III
Moritz J. Reike(University of British Columbia), Peter C. Black(University of British Columbia), Joshua J. Meeks(Northwestern University), Peter J. Goebell(Universitätsklinikum Erlangen), Tahlita C.M. Zuiverloon(Erasmus MC), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Trine Strandgaard(Aarhus University), Bernd J. Schmitz‐Dräger, Lars Dyrskjøt(Aarhus University Hospital), Stephen B. Williams(Cedars-Sinai Medical Center), Molly A. Ingersoll(Centre National de la Recherche Scientifique), Tilman Todenhöfer(University of British Columbia), David C. Müller(Imperial College London), Roland Seiler(University of British Columbia), John P. Sfakianos(Mount Sinai Medical Center), Amir Horowitz(Cancer Institute (WIA)), Roman Nawroth(TUM Klinikum)
Cited by 6
Related Papers
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
|JAMA Oncology|2019|992
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
|Circulation|1998|804